WUXI XDC(02268) announced a profit increase of over 50% year-on-year in the first half of the year, bringing joy to shareholders.

WUXI XDC (02268) announced that the group expects its revenue to grow by over 60% year-on-year in the first half of 2025, and the adjusted net profit (excluding interest income and expenses) to increase by over 67%, with the net profit growing by over 50%. The company believes that the expected growth is mainly attributed to the following factors: the continued strong downstream demand for Antibody-Drug Conjugates (ADC) and the broader biopharmaceutical industry; the group obtaining important market share in the biopharmaceutical CRDMO sector through its solid leading position and competitive advantages; and the rapid ramp-up of production capacity of the group's new production lines, with production facilities maintaining high utilization rates and continuous improvement in operational efficiency.